Maria de los Angeles Chavez Corona*, Barbara Perez-Aguilar, Raul Valencia Lopez, Daniel R Hernandez Salcedo and Sara Isais Millan
Autoimmune myopathies result from direct or indirect injury to muscle fibers mediated by the immune system. The term myositis is generally interchangeable with “Idiopathic Inflammatory Myopathy”, which refers to primary autoimmune muscle diseases. These include dermatomyositis, inclusion body myositis, antisynthetase syndrome, and Immune Mediated Necrotizing Myopathy (IMNM). Other known causes of inflammatory myopathies include infections, drugs, mixed connective tissue diseases and cancer. In 2017, the European neuromuscular centre described two subtypes of IMNM, each mediated by a different antibody: Anti-SRP and Anti-3-Hydroxy-3-Methyl Glutaryl Coenzyme A reductase (Anti-HMG-CoA), each presents with a different clinical and histopathological course. The first is associated with a more aggressive disease and a low response to conventional immunotherapy. In this review, however, we will focus on the latter, MNIM related to anti-HMG-CoA.
